The global aortic valve replacement market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 10% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.
Aortic valve replacement is a procedure to treat diseases affecting the valves that control blood flow through the heart. It helps restore normal blood flow, reduce symptoms, prolong life, and preserve the function of the heart muscle. It is usually performed through the traditional open-heart surgery, which involves incising the chest or using minimally invasive (MI) methods that require smaller incisions in the chest or a catheter inserted in the leg. Nowadays, leading players are introducing artificial valves, which are made using carbon-coated plastic or tissue from cows, pigs, or donors.
In confluence with the increasing demand for MIS, the growing prevalence of valvular diseases represents one of the key factors stimulating the market growth. Moreover, governments of numerous countries are undertaking various initiatives for managing valvular diseases, which, in turn, is driving the market. Apart from this, as valves become narrow and stiff from aging, the growing geriatric population is contributing to market growth. The favorable reimbursement policies in hospitals are also influencing the market. Furthermore, the increasing number of approvals for innovative products is anticipated to bolster the market growth. For instance, JenaValve Technology, Inc., a developer and manufacturer of transcatheter aortic valve replacement (TAVR) system, received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) in 2020. This designation is for severe aortic regurgitation (AR) and AR dominant mixed aortic valve disease, which is a life-threatening and seriously debilitating condition in patients.
IMARC Group provides an analysis of the key trends in each sub-segment of the global aortic valve replacement market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, surgery, product and end use.
Breakup by Surgery:
Breakup by Product:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Anteris Technologies Ltd., Boston Scientific Corporation, Coroneo Inc., CryoLife Inc., Edward Lifesciences Corporation, JenaValve Technology Inc., LifeNet Health Inc., LivaNova PLC, Medtronic plc and Thubrikar Aortic Valve Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Surgery, Product, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Anteris Technologies Ltd., Boston Scientific Corporation, Coroneo Inc., CryoLife Inc., Edward Lifesciences Corporation, JenaValve Technology Inc., LifeNet Health Inc., LivaNova PLC, Medtronic plc and Thubrikar Aortic Valve Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at